Position in ANL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$14,375,000
+$10,648,850 QoQ
Shares Held
1,250,000
+132.1% QoQ
Ownership
1.94%
of shares outstanding
% of Portfolio
0.72%
of 13F equity value
Holder Rank
#7
of 42 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ANL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Casdin Capital, LLC holds $1,258,350,419 across 31 Biotechnology names. ANL ranks #15 (1.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
2,577,333 | $482,682,924 | |
| 2 | RLAY |
Relay Therapeutics, Inc.
|
16,035,240 | $300,019,340 | |
| 3 | GPCR |
Structure Therapeutics Inc.
|
1,175,000 | $63,062,250 | |
| 4 | DNLI |
Denali Therapeutics Inc.
|
2,045,000 | $52,597,400 | |
| 5 | NGNE |
Neurogene Inc.
|
1,545,361 | $48,601,603 | |
| 6 | BEAM |
Beam Therapeutics Inc.
|
1,350,000 | $46,332,000 | |
| 7 | SRRK |
Scholar Rock Holding Corp
|
665,000 | $36,575,000 | |
| 8 | MAZE |
Maze Therapeutics, Inc.
|
843,857 | $25,180,692 |
All Filings in ANL
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $14,375,000 | 1,250,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $3,726,150 | 538,461 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||